CHINESE JOURNAL OF MEDICINAL GUIDE >
Visualization Analysis of the Development of Physiologically Based Pharmacokinetic Models in Renal Tissue Applications
Received date: 2025-03-18
Revised date: 2025-06-23
Accepted date: 2025-11-15
Online published: 2026-02-11
Objective： To conduct a bibliometric analysis， providing a multidimensional assessment of the research status and development trends in the application of physiologically based pharmacokinetic （PBPK） models to renal tissue. This aims to offer novel insights for the clinical utilization of PBPK models in addressing kidney-related issues.Methods： The Web of Science core collection database was systematically searched for articles on the application of PBPK model in the field of kidney from January 1， 2004 to December 31， 2024. Bibliometric methods were employed， utilizing visualization tools （VOSviewer， CiteSpace， Scimago Graphica， Pajek） to conduct an in-depth analysis of country/region distribution， institutions， journals， author cooperation， and keyword co-occurrence. Corresponding knowledge maps were constructed.Results： This study included 780 articles. The annual number of published articles exhibited a consistent upward trend from 2004 to 2024. In terms of the number of published articles， the top three countries were the United States， China， and the United Kingdom； the most prolific author was Glatting G （20 articles）； Certara UK Ltd （37 articles） and Drug Metabolism and Disposition （43 articles） were the most prolific institution and journal in this field. Keyword analysis revealed enduring research hotspots including renal clearance， nephrotoxicity， drug exposure， risk assessment， and tissue distribution. Current research frontiers primarily focus on drug-drug interactions， pharmacodynamics， medication safety， and chronic kidney disease.Conclusion： Research interest in the application of PBPK models to renal tissue has steadily increased between 2004 and 2024. Future research directions and hotspots are anticipated to center on applications in drug-drug interactions， medication safety， and chronic kidney disease.
Key words： Physiologically based pharmacokinetic model； ; Kidney； ; Drug； ; Bibliometrics； ; Visualization analysis
Jia-Kai Li
.
Visualization Analysis of the Development of
Physiologically Based Pharmacokinetic Models in Renal Tissue Applications
［1］ Espié P， Tytgat D， Sargentini-Maier ML， et al. Physiologically based pharmacokinetics （PBPK）［J］.Drug Metab Rev， 2009， 41（3）： 391-407.
［2］ Zhao P， Zhang L， Grillo JA， et al. Applications of physiologically based pharmacokinetic （PBPK） modeling and simulation during regulatory review［J］.Clin Pharmacol Ther， 2011， 89（2）： 259-67.
［3］ 苏霞，何月珍，高玉成，等.中国定量药理学研究的文献计量分析（2017—2022）［J］.中国医院药学杂志，2024，44（23）：2673-2679.
［4］ Masereeuw R， Russel FG. Mechanisms and clinical implications of renal drug excretion［J］.Drug Metab Rev， 2001， 33（3-4）： 299-351.
［5］ Rowland M， Peck C， Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science［J］.Annu Rev Pharmacol Toxicol， 2011， 51： 45-73.
［6］ Ladumor MK， Thakur A， Sharma S， et al. A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic （PBPK） modelling and simulation［J］.Sci Rep， 2019， 9（1）： 9709.
［7］ 王迪，张娟，李睿，等.生理药代动力学软件模拟技术在药物研发和评价中的应用［J］.药学研究，2022，41（3）：195-201.
［8］ 常咏春，盛莉.生理药动学模型在特殊人群药物相互作用研究中的应用进展［J］.中国药理学与毒理学杂志，2024，38（11）：872-879.
［9］ Gao J， Meng T， Li M， et al. Global trends and frontiers in research on coronary microvascular dysfunction： a bibliometric analysis from 2002 to 2022［J］.Eur J Med Res， 2022，27（1）： 233.
［10］ 龙豪，陆洁，谷俊远，等.生物膜与牙周炎研究现状与热点的可视化分析［J］.实用临床医药杂志，2024，28（5）：10-16.
［11］ Jiang S， Liu Y， Zheng H， et al. Evolutionary patterns and research frontiers in neoadjuvant immunotherapy： a bibliometric analysis［J］.Int J Surg， 2023，109（9）：2774-2783.
［12］ Dagli N， Haque M， Kumar Set al. A Bibliometric analysis of literature on the impact of diet on oral health［J］.Cureus， 2024，16（4）：e59418.
［13］ Zheng D， Vaughn S， Gould M， et al. Bibliometric analysis of depression in post-stroke patients［J］.Int J Emerg Med， 2024，17（1）：139.
［14］ Lu C，Bing Z，Bi Z，et al.Top-100 most cited publications concerning network pharmacology： a bibliometric analysis［J］.Evid Based Complement Alternat Med，2019：1704816.
［15］ 曹泽锟，苏奕晨，谷俊远，等.基于CiteSpace和VOSviewer的抗菌药物治疗腹腔感染研究热点的可视化分析［J］.实用临床医药杂志，2023，27（20）：74-79，85.
［16］ 谢丽.解读高校图书馆信息素养教育脉络［J］.文化产业，2024，（34）：111-113.
［17］ Zamir A， Rasool MF， Imran I， et al. Physiologically based pharmacokinetic model to predict metoprolol disposition in healthy and disease populations［J］.ACS Omega， 2023，8（32）：29302-29313.
［18］ Li Z， Litchfield J， Tess DA， et al. A physiologically based in silico tool to assess the risk of drug-related crystalluria［J］.J Med Chem， 2020，63（12）：6489-6498.
［19］ Szeto KX， Le Merdy M， Dupont B， et al. PBPK modeling approach to predict the behavior of drugs cleared by kidney in pregnant subjects and fetus［J］.AAPS J， 2021，23（4）：89.
［20］ 杨妍妍，谢潘潘，史爱欣.基于生理药代动力学模型从体外及临床前数据对人体药代动力学预测及优化应用状况［J］.中国临床药理学杂志，2021，37（20）：2853-2856.
［21］ Du H， Li Z， Yang Y， et al. New insights into the vancomycin-induced nephrotoxicity using in vitro metabolomics combined with physiologically based pharmacokinetic modeling［J］.J Appl Toxicol， 2020，40（7）：897-907.
［22］ Hsu V， De LT Vieira M， Zhao P， et al. Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters， using physiologically based pharmacokinetic modelling and simulations［J］.Clin Pharmacokinet， 2014，53（3）：283-293.
［23］ Tan SPF， Willemin ME， Snoeys J， et al. Development of 4-pyridoxic acid PBPK model to support biomarker-informed evaluation of OAT1/3 inhibition and effect of chronic kidney disease［J］.Clin Pharmacol Ther， 2023，114（6）：1243-1253.
/
| 〈 |
|
〉 |